Longitudinal MRI Assessment in Patients With Diffuse Low-grade Gliomas
Completed
- Conditions
- Low-grade Glioma
- Registration Number
- NCT04346472
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Retrospective longitudinal follow-up in patients with diffuse low-grade glioma with multimodal MRI assessment
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Longitudinal variation of the relative regional cerebral blood volume 1 day Longitudinal variation of the relative regional cerebral blood volume from first pass perfusion imaging data for each MRI performed
- Secondary Outcome Measures
Name Time Method Collection of clinical varaibles 1 day Collection of clinical varaibles
Collection of radiological 1 day Collection of radiological
Collection of histological 1 day Collection of histological
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the progression of diffuse low-grade gliomas as observed through longitudinal MRI assessments in NCT04346472?
How does the relative regional cerebral blood volume correlate with tumor heterogeneity and prognosis in low-grade glioma patients from the Montpellier cohort study?
Are there specific biomarkers identified in the University Hospital Montpellier trial that could enhance patient selection for targeted therapies in diffuse low-grade gliomas?
What adverse events are associated with multimodal MRI assessments in longitudinal studies of low-grade glioma patients, and how are they managed clinically?
How do the findings from NCT04346472 compare with other observational studies on low-grade gliomas regarding treatment response and disease progression markers?
Trial Locations
- Locations (1)
Uhmontpellier
🇫🇷Montpellier, France
Uhmontpellier🇫🇷Montpellier, France